Parameters such as bone mineral density (BMD), trabecular thickness, and bone volume fraction (BV/TV) remained unchanged, suggesting that FGF21’s metabolic benefits do not necessarily compromise skeletal integrity in diabetes. This evidence concerns the gene FGF21 and diabetes mellitus.